Quick Answer
Anika Therapeutics, Inc. reported Diluted EPS of $0.76 per share (loss) for fiscal year 2025.
Anika Therapeutics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$0.76 | +80.2% |
| 2024 | -$3.83 | +32.1% |
| 2023 | -$5.64 | -452.9% |
| 2022 | -$1.02 | -464.3% |
| 2021 | $0.28 | +116.6% |
| 2020 | -$1.69 | -189.4% |
| 2019 | $1.89 | +48.8% |
| 2018 | $1.27 | -39.8% |
| 2017 | $2.11 | -1.9% |
| 2016 | $2.15 | +7.0% |
| 2015 | $2.01 | -19.9% |
| 2014 | $2.51 | +80.6% |
| 2013 | $1.39 | +69.5% |
| 2012 | $0.82 | +32.3% |
| 2011 | $0.62 | +93.8% |
| 2010 | $0.32 | +0.0% |
| 2009 | $0.32 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.16 | +92.1% | +42.9% |
| June 30, 2025 | -$0.28 | — | +17.6% |
| March 31, 2025 | -$0.34 | -9.7% | +83.3% |
| September 30, 2024 | -$2.03 | -351.1% | — |
| June 30, 2024 | $0.00 | +100.0% | +100.0% |
| March 31, 2024 | -$0.31 | +56.3% | +31.1% |
| September 30, 2023 | -$0.45 | -55.2% | -136.8% |
| June 30, 2023 | -$0.19 | +5.0% | +73.2% |
- Anika Therapeutics, Inc. showed an increase of +80.2% in Diluted EPS compared to the prior fiscal year.
- Over the 2009–2025 period, Anika Therapeutics, Inc.’s diluted eps has declined by 337.5% (from $0.32 per share to $0.76 per share (loss)).
- The most recent figure is from Anika Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 3, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: